Gifu University Hospital and our company have started joint research on N-NOSE. This study examines the usefulness of “N-NOSE” cancer risk assessment in the treatment of solid tumors (esophagus, stomach, large intestine, pancreas, milk). Both sides will work on this research with the expectation that “N-NOSE” will go beyond the framework of screening tests and be established as an important test method in clinical practice.
We as HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative: Takaaki Hirotsu (Hereinafter referred to as “HIROTSU”) are pleas . . .
2024.04.01On March 18, 2024, an reveiw articles on cancer screening by a third-party research team (Romania) was published in "Cancers", an oncology journ . . .
2024.03.29HIROTSU Bioscience Inc. (Head Office: Chiyoda-ku, Tokyo, Representative: Takaaki Hirotsu, hereinafter referred to as “HIROTSU) has verified the . . .
2024.02.29